Submandibular gland-sparing radiation therapy for locally advanced oropharyngeal squamous cell carcinoma: patterns of failure and xerostomia outcomes

Table 5 Literature on submandibular gland-sparing IMRT for oropharynx cancer

Study	N	Definitive RT	Mean cSMG dose (Gy)	Disease outcome	Late xerostomia
Univ. of Washington (present report)	76	86%	30.7	No peri-SMG recurrence	23% grade 2+ at 6 months No permanent grade 3 +
Helsinki Univ., Finland [24]	50	49%*	27.8	No peri-SMG recurrence	No permanent grade 3+
VU Univ. Med. Ctr., The Netherlands [30]	20	100%	34.1	No peri-SMG nodal recurrence	Not reported
Univ. of Michigan [13]	17†	100%	~43	No contralateral level I recurrence	No grade 3+
Centre Eugene Marquis, France [31]	8	100%	33.8	No peri-SMG recurrence	No grade 3+

*Number is from larger series including other disease sites.
†Patients with contralateral SMG dose <50 Gy were extracted from a larger group of 78 patients (personal communication with Avraham Eisbruch). Of larger group, 92% had oropharynx cancer.

ISSN: 1748-717X